Treatment-Resistant Major Depressive Disorder
The combination of sertraline and aripiprazole is indicated for treatment-resistant major depressive disorder (MDD) in patients who have shown an inadequate response to antidepressant monotherapy.
Primary Indication
This combination specifically targets treatment-resistant depression - defined as MDD that has not adequately responded to first-line antidepressant treatment. The FDA-approved indication for aripiprazole is as adjunctive therapy to antidepressants for treating MDD 1.
Clinical Context and Evidence
When to Consider This Combination
The evidence supports using aripiprazole augmentation when:
- A patient has failed to achieve remission after 8-12 weeks of adequate antidepressant monotherapy (typically sertraline 100 mg/day) 2
- First-line SSRI treatment has produced insufficient symptom relief
- The patient meets DSM-5 criteria for major depressive disorder with moderate to severe symptoms
The most robust evidence comes from a 2018 randomized, double-blind trial showing that aripiprazole/sertraline combination (ASC) produced significantly greater improvement in MADRS scores compared to sertraline alone (-9.2 vs -7.2; P = 0.0070) in patients who had inadequate response to sertraline 100 mg/day 2.
Efficacy Profile
Multiple studies demonstrate:
- Response rates of 75% in treatment-resistant populations 3
- Remission rates of 22-31% in augmentation trials 4
- Early onset of action within 1-2 weeks, with significant improvements in HAM-D17 scores by week 1 and sustained through week 4 3
- Particular improvement in work/social functioning and somatic symptoms 3
The 2023 American College of Physicians guideline notes that augmentation with aripiprazole showed higher remission rates (55.4%) compared to bupropion augmentation (34.0%; P = 0.031) in one trial 5.
Important Clinical Considerations
Screening Requirements
Before initiating sertraline, patients MUST be screened for bipolar disorder risk 1. This is critical because:
- Sertraline is NOT approved for bipolar depression 1
- Treating bipolar depression with antidepressants alone may precipitate manic/mixed episodes
- Required screening includes detailed psychiatric history and family history of suicide, bipolar disorder, and depression
Dosing Strategy
Based on clinical trial data:
- Aripiprazole: 3-12 mg/day (most commonly 2.5-3 mg/day in augmentation) 2, 3
- Sertraline: 100 mg/day (standard dose for treatment resistance) 2
- Lower doses of aripiprazole (1.5-3 mg/day) have shown efficacy with better tolerability 3
Safety Profile
The combination is generally well-tolerated 2:
- Akathisia is the most notable adverse event (12.9% vs 3.4% with placebo), though typically mild-to-moderate 2
- Discontinuation rates due to adverse events are low (1.9%) 2
- Weight gain shows minimal trend over 6 weeks 6
- Monitor for serotonin syndrome, though risk is low with this specific combination
Common Pitfalls to Avoid
- Do not use this combination for bipolar depression - sertraline is contraindicated 1
- Do not combine with MAOIs - absolute contraindication due to serotonin syndrome risk 1
- Screen for narrow-angle glaucoma - sertraline can trigger angle-closure attacks 1
- Monitor for akathisia early - most common reason for discontinuation, though infrequent 2
Alternative Context
While the primary evidence supports treatment-resistant MDD, there is emerging preliminary data suggesting potential benefit in refractory functional dizziness disorders including PPPD 7, though this remains investigational. Additionally, trials are underway examining this combination for bipolar depression 8, but this is NOT currently an approved indication.